Page last updated: 2024-12-05

dixyrazine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

dixyrazine: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID17182
CHEMBL ID3275586
CHEBI ID135695
SCHEMBL ID184504
MeSH IDM0060330

Synonyms (46)

Synonym
2-(2-(4-(2-methyl-3-(10h-phenothiazin-10-yl)propyl)piperazin-1-yl)ethoxy)ethanol
einecs 219-591-3
brn 0768050
ethanol, 2-(2-(4-(2-methyl-3-phenothiazin-10-ylpropyl)-1-piperazinyl)ethoxy)-
(2-methyl-3-(1-hydroxyethoxyethyl-4-piperazinyl)propyl)-10-phenothiazine
esucos
10-(2-methyl-3-(1-hydroxyethoxyethyl-4-piperazinyl)propyl)phenothiazine
ucb 3412
2-(2-(4-(2-methyl-3-phenothiazin-10-ylpropyl)-1-piperazinyl)ethoxy)ethanol
10-(3-(4-hydroxyethoxyethyl-1-piperazinyl)-2-methylpropyl)phenothiazine
dixyrazine
CHEBI:135695
2-[2-[4-(2-methyl-3-phenothiazin-10-ylpropyl)piperazin-1-yl]ethoxy]ethanol
esucos (tn)
2470-73-7
D07865
unii-7h368w3ayc
7h368w3ayc ,
ethanol,2-[2-[4-[2-methyl-3-(10h-phenothiazin-10-yl)propyl]-1-piperazinyl]ethoxy]-
j21.394b ,
ethanol, 2-(2-(4-(2-methyl-3-(10h-phenothiazin-10-yl)propyl)-1-piperazinyl)ethoxy)-
dixyrazine [mi]
dyxirazine
dixyrazine [who-dd]
ucb-3412
dixyrazine [mart.]
CHEMBL3275586
SCHEMBL184504
ethanol, 2-[2-[4-[2-methyl-3-(10h-phenothiazin-10-yl)propyl]-1-piperazinyl]ethoxy]-
esocalm
metronal
MSYUMPGNGDNTIQ-UHFFFAOYSA-N
ethanol, 2-[2-[4-(2-methyl-3-phenothiazin-10-ylpropyl)-1-piperazinyl]ethoxy]-
roscal
u. c. b. 3412
10-[3-(4-hydroxyethoxyethyl-1-piperazinyl)-2-methylpropyl]phenothiazine
2-(2-(4-[2-methyl-3-(10h-phenothiazin-10-yl)propyl]-1-piperazinyl)ethoxy)ethanol #
dixyrizine
AKOS027379626
HY-U00153
CS-7192
Q2759774
DB13784
bdbm50497152
MS-27562
DTXSID10947639

Research Excerpts

Treatment

ExcerptReferenceRelevance
"Pretreatment with dixyrazine 10 mg/kg completely prevented the brain oedema and significantly reduced the albumin increase in CSF."( Dixyrazine, a phenothiazine derivative, can prevent brain oedema induced by intracarotid injection of protamine sulphate.
Johansson, BB; Westergren, I, 1991
)
2.05

Toxicity

ExcerptReferenceRelevance
" The results justify further studies on the antineoplastic and adverse effects pertaining to interaction between anthracyclines and antiemetics."( Epirubicin cytotoxicity but not oxygen radical formation is enhanced by four different antiemetics.
Grankvist, K; Henriksson, R, 1989
)
0.28

Compound-Compound Interactions

All patients were treated with imipramine (100-200 mg-day) combined with either placebo, diazepam (10 mg/day) or dixyrazine (50 mg/ day) for 8 weeks.

ExcerptReferenceRelevance
" This treatment was combined with either placebo, diazepam (10 mg/day) or dixyrazine (50 mg/day)."( Comparison of the serum levels in primary non-agitated depressed out-patients treated with imipramine in combination with placebo, diazepam or dixyrazine.
Feet, PO; Holm, V; Larsen, S; Liden, A; Lillevold, PE; Robak, OH, 1987
)
0.7
" All patients were treated with imipramine (100-200 mg-day) combined with either placebo, diazepam (10 mg/day) or dixyrazine (50 mg/day) for 8 weeks."( A double blind study in out-patients with primary non-agitated depression treated with imipramine in combination with placebo, diazepam or dixyrazine.
Feet, PO; Larsen, S; Robak, OH, 1985
)
0.68

Bioavailability

ExcerptReferenceRelevance
" Dixyrazine was found to have a very low and interindividually varying bioavailability; in the fasting state, dixyrazine bioavailability was only 1% in one subject, 3-6% in five others, and 11 and 24% in the remaining two subjects."( Pharmacokinetics of dixyrazine: low bioavailability, improved by food intake.
Kroon, L; Lidén, A; Liedholm, H; Melander, A; Wåhlin-Boll, E, 1985
)
1.5

Dosage Studied

ExcerptRelevanceReference
" No significant correlation was found between the dosage and the serum concentration of imipramine or desipramine."( Comparison of the serum levels in primary non-agitated depressed out-patients treated with imipramine in combination with placebo, diazepam or dixyrazine.
Feet, PO; Holm, V; Larsen, S; Liden, A; Lillevold, PE; Robak, OH, 1987
)
0.47
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
phenothiazines
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID1148004Oleyl alcohol-water partition coefficient, Rm of the compound measured at 0% methanol by reverse-phase thin layer chromatography1977Journal of medicinal chemistry, Mar, Volume: 20, Issue:3
Quantitative correlations between albumin binding constants and chromatographic Rm values of phenothiazine derivatives.
AID1148006Binding affinity to bovine serum albumin by circular dichroic probe technique1977Journal of medicinal chemistry, Mar, Volume: 20, Issue:3
Quantitative correlations between albumin binding constants and chromatographic Rm values of phenothiazine derivatives.
AID1148003Dissociation constant, pKa of the compound by UV-visible spectrophotometer analysis1977Journal of medicinal chemistry, Mar, Volume: 20, Issue:3
Quantitative correlations between albumin binding constants and chromatographic Rm values of phenothiazine derivatives.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (66)

TimeframeStudies, This Drug (%)All Drugs %
pre-199048 (72.73)18.7374
1990's11 (16.67)18.2507
2000's6 (9.09)29.6817
2010's1 (1.52)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 21.09

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index21.09 (24.57)
Research Supply Index4.50 (2.92)
Research Growth Index3.95 (4.65)
Search Engine Demand Index23.28 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (21.09)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials19 (27.14%)5.53%
Reviews0 (0.00%)6.00%
Case Studies2 (2.86%)4.05%
Observational0 (0.00%)0.25%
Other49 (70.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]